These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 32564027

  • 1. Use Motives of Patients with Amphetamine-Type Stimulants Use Disorder and Attention-Deficit/Hyperactivity Disorder.
    Thurn D, Riedner A, Wolstein J.
    Eur Addict Res; 2020; 26(4-5):254-262. PubMed ID: 32564027
    [Abstract] [Full Text] [Related]

  • 2. Look west for Australian evidence of the relationship between amphetamine-type stimulant prescribing and meth/amphetamine use.
    Whitely M, Allsop S.
    Drug Alcohol Rev; 2020 Jul; 39(5):519-524. PubMed ID: 32314469
    [Abstract] [Full Text] [Related]

  • 3. Development and Validation of the Amphetamine-Type Stimulants Motive Questionnaire in a Clinical Population.
    Thurn D, Kuntsche E, Weber JA, Wolstein J.
    Front Psychiatry; 2017 Jul; 8():183. PubMed ID: 28993742
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M, Dahl AA, Martinsen EW, Klungsøyr O, Haavik J, Peleikis DE.
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [Abstract] [Full Text] [Related]

  • 5. Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study.
    Spencer TJ, Landgraf JM, Adler LA, Weisler RH, Anderson CS, Youcha SH.
    J Clin Psychiatry; 2008 Nov; 69(11):1766-75. PubMed ID: 19026251
    [Abstract] [Full Text] [Related]

  • 6. Attention deficit hyperactivity disorder and future alcohol outcomes: Examining the roles of coping and enhancement drinking motives among young men.
    Grazioli VS, Gmel G, Rougemont-Bücking A, Baggio S, Daeppen JB, Studer J.
    PLoS One; 2019 Nov; 14(6):e0218469. PubMed ID: 31216319
    [Abstract] [Full Text] [Related]

  • 7. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.
    Perugi G, Vannucchi G.
    Expert Opin Pharmacother; 2015 Nov; 16(14):2193-204. PubMed ID: 26364896
    [Abstract] [Full Text] [Related]

  • 8. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
    Kollins SH.
    Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
    [Abstract] [Full Text] [Related]

  • 9. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA, Pliszka SR.
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [Abstract] [Full Text] [Related]

  • 10. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial.
    Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ, Babb D, Bai Y, Eberly LE, Nunes EV, Grabowski J.
    JAMA Psychiatry; 2015 Jun; 72(6):593-602. PubMed ID: 25887096
    [Abstract] [Full Text] [Related]

  • 11. The nonmedical use of prescription ADHD medications: results from a national Internet panel.
    Novak SP, Kroutil LA, Williams RL, Van Brunt DL.
    Subst Abuse Treat Prev Policy; 2007 Oct 31; 2():32. PubMed ID: 17974020
    [Abstract] [Full Text] [Related]

  • 12. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
    Merkel RL, Kuchibhatla A.
    Expert Opin Drug Saf; 2009 Nov 31; 8(6):655-68. PubMed ID: 19785509
    [Abstract] [Full Text] [Related]

  • 13. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV, Wilens TE.
    J Clin Psychiatry; 2007 Nov 31; 68 Suppl 11():15-22. PubMed ID: 18307377
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J.
    Clin Ther; 2009 Jan 31; 31(1):142-76. PubMed ID: 19243715
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A randomized, double-blind, 3-way crossover, analog classroom study of SHP465 mixed amphetamine salts extended-release in adolescents with ADHD.
    Wigal S, Lopez F, Frick G, Yan B, Robertson B, Madhoo M.
    Postgrad Med; 2019 Apr 31; 131(3):212-224. PubMed ID: 30681017
    [Abstract] [Full Text] [Related]

  • 19. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.
    Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S.
    N Engl J Med; 2019 Mar 21; 380(12):1128-1138. PubMed ID: 30893533
    [Abstract] [Full Text] [Related]

  • 20. Attention deficit hyperactivity disorder and substance use disorders.
    Bukstein OG.
    Curr Top Behav Neurosci; 2012 Mar 21; 9():145-72. PubMed ID: 21789746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.